Drug intelligence / Profile preview

BA-240

Development stage: Preclinical
Lead developer: BioAxone Therapeutics
Modality: Small Molecules

Overview

**BA-240** is a small molecule drug developed by BioAxone Therapeutic, Inc., acting as an inhibitor of Rho-related GTP-binding protein RhoB (RHOB), a member of the Rho GTPase family involved in regulating actin cytoskeleton dynamics, cell migration, and vesicular trafficking. It is being investigated for nervous system diseases, particularly optic nerve injuries, and eye diseases such as glaucoma, where RHOB inhibition may promote neuroprotection and axonal regeneration by modulating pathways implicated in neurodegeneration and retinal ganglion cell death.

Targets

RHOB (Ras homolog family member B)

Beyond the preview

Go deeper on BA-240.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BA-240.

Explore the full profile